Form 8-K - Current report:
SEC Accession No. 0001723128-25-000033
Filing Date
2025-07-21
Accepted
2025-07-21 07:41:03
Documents
14
Period of Report
2025-07-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K amrx-20250716.htm   iXBRL 8-K 30140
2 EX-99.1 amrx-q22025x8xkxpreannounc.htm EX-99.1 141572
6 GRAPHIC amneala.jpg GRAPHIC 2670
  Complete submission text file 0001723128-25-000033.txt   307570

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT amrx-20250716.xsd EX-101.SCH 1876
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT amrx-20250716_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT amrx-20250716_pre.xml EX-101.PRE 12599
17 EXTRACTED XBRL INSTANCE DOCUMENT amrx-20250716_htm.xml XML 2729
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 251135729
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)